• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Corrigendum re "Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma" [Eur Urol 2020;78:907-15].

作者信息

Teo Min Yuen, Mota Jose Mauricio, Whiting Karissa A, Li Han A, Funt Samuel A, Lee Chung-Han, Solit David B, Al-Ahmadie Hikmat, Milowsky Matthew I, Balar Arjun V, Pietzak Eugene, Dalbagni Guido, Bochner Bernard H, Ostrovnaya Irina, Bajorin Dean F, Rosenberg Jonathan E, Iyer Gopa

机构信息

Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, New York, NY, USA.

Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

出版信息

Eur Urol. 2021 May;79(5):e158-e159. doi: 10.1016/j.eururo.2021.01.031. Epub 2021 Feb 9.

DOI:10.1016/j.eururo.2021.01.031
PMID:33579575
Abstract
摘要

相似文献

1
Corrigendum re "Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma" [Eur Urol 2020;78:907-15].
Eur Urol. 2021 May;79(5):e158-e159. doi: 10.1016/j.eururo.2021.01.031. Epub 2021 Feb 9.
2
Re: Ming Yuen Teo, Jose Mauricio Mota, Karissa A. Whiting, et al. Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma. Eur Urol 2020;78:907-15: Linking FGFR3 Mutation Status and Luminal Papillary Subtype to Response to Cisplatin-based Chemotherapy in Bladder Cancer.回复：明·阮·蒂奥、何塞·毛里西奥·莫塔、卡丽莎·A·怀廷等。成纤维细胞生长因子受体3改变状态与局部晚期和转移性尿路上皮癌对铂类化疗的不同敏感性相关。《欧洲泌尿外科杂志》2020年；78卷：907 - 15页：将FGFR3突变状态和管腔乳头状亚型与膀胱癌对顺铂化疗的反应联系起来。
Eur Urol. 2021 Jun;79(6):e182-e183. doi: 10.1016/j.eururo.2021.03.028. Epub 2021 Apr 8.
3
Fibroblast Growth Factor Receptor 3 Alteration Status is Associated with Differential Sensitivity to Platinum-based Chemotherapy in Locally Advanced and Metastatic Urothelial Carcinoma.成纤维细胞生长因子受体 3 改变状态与局部晚期和转移性尿路上皮癌对铂类化疗的敏感性差异相关。
Eur Urol. 2020 Dec;78(6):907-915. doi: 10.1016/j.eururo.2020.07.018. Epub 2020 Aug 1.
4
Corrigendum re: "Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens" [Eur Urol 2018;73:462-8].关于《阿替利珠单抗用于铂类治疗的局部晚期或转移性尿路上皮癌：按既往治疗方案数量划分的结果》[《欧洲泌尿外科杂志》2018年；73卷：462 - 468页]的勘误
Eur Urol. 2019 Mar;75(3):e82-e83. doi: 10.1016/j.eururo.2018.11.032. Epub 2018 Nov 28.
5
Re: Jose Luis Perez-Gracia, Yohann Loriot, Jonathan E. Rosenberg, et al. Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens. Eur Urol 2018;73:462-8.回复：何塞·路易斯·佩雷斯 - 格拉西亚、约安·洛里奥、乔纳森·E·罗森伯格等。阿替利珠单抗用于铂类治疗的局部晚期或转移性尿路上皮癌：根据既往治疗方案数量的疗效。《欧洲泌尿外科杂志》2018年；73卷：462 - 468页。
Eur Urol. 2018 Jul;74(1):e12-e13. doi: 10.1016/j.eururo.2018.03.034. Epub 2018 Apr 12.
6
Reply to Francesco Massari and Vincenzo Di Nunno's Letter to the Editor re: Jose Luis Perez-Gracia, Yohann Loriot, Jonathan E. Rosenberg, et al. Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens. Eur Urol 2018;73:462-8.对弗朗切斯科·马萨里和文森佐·迪农诺致编辑的信的回复，信的主题为：何塞·路易斯·佩雷斯 - 格拉西亚、约安·洛里奥、乔纳森·E·罗森伯格等人。阿替利珠单抗治疗铂类治疗后的局部晚期或转移性尿路上皮癌：根据既往治疗方案数量的疗效。《欧洲泌尿外科杂志》2018年；73卷：462 - 468页。
Eur Urol. 2018 Jul;74(1):e14. doi: 10.1016/j.eururo.2018.03.035. Epub 2018 Apr 13.
7
Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial.阿维鲁单抗治疗铂类治疗失败后的转移性尿路上皮癌（JAVELIN Solid Tumor）：一项开放标签、1 期试验两个扩展队列的汇总结果。
Lancet Oncol. 2018 Jan;19(1):51-64. doi: 10.1016/S1470-2045(17)30900-2. Epub 2017 Dec 5.
8
DNA Damage Response and Repair Gene Alterations Are Associated with Improved Survival in Patients with Platinum-Treated Advanced Urothelial Carcinoma.DNA 损伤反应和修复基因改变与铂类治疗的晚期尿路上皮癌患者的生存改善相关。
Clin Cancer Res. 2017 Jul 15;23(14):3610-3618. doi: 10.1158/1078-0432.CCR-16-2520. Epub 2017 Jan 30.
9
FDA Approval Summary: Atezolizumab for the Treatment of Patients with Progressive Advanced Urothelial Carcinoma after Platinum-Containing Chemotherapy.美国食品药品监督管理局批准摘要：阿替利珠单抗用于治疗含铂化疗后进展期晚期尿路上皮癌患者。
Oncologist. 2017 Jun;22(6):743-749. doi: 10.1634/theoncologist.2017-0087. Epub 2017 Apr 19.
10
Commentary on "DNA damage response and repair gene alterations are associated with improved survival in patients with platinum-treated advanced urothelial carcinoma.".关于“DNA损伤反应与修复基因改变与铂类治疗的晚期尿路上皮癌患者生存率提高相关”的评论
Urol Oncol. 2018 Jul;36(7):345-346. doi: 10.1016/j.urolonc.2018.05.011. Epub 2018 May 30.